Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series

ConclusionsRetreatment with ipi  + nivo may be considered an option in carefully selected, well-informed patients. More research is required to delineate the benefits and risks with this approach.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research